地西他滨治疗老年急性白血病4例并文献复习

详细信息

收稿日期: 2012-02-24

Received Date: 24 February 2012

摘要: 目的:探讨地西他滨4 d疗程方案治疗老年急性白血病的疗效及安全性。方法:应用地西他滨30 mg/m² 4 d疗程方案治疗4例老年急性髓系白血病,并评价其疗效和不良反应。结果:2例患者应用地西他滨4疗程后达完全缓解,1例在3疗程后获部分缓解,1例1疗程后因多器官功能衰竭死亡。4例患者治疗过程中均出现较明显的粒细胞和血小板减少。结论:地西他滨是治疗老年急性髓系白血病的有效选择,疗效较好,不良反应可以耐受。4 d方案在疗效和耐受性上与3 d和5 d方案相比,无明显差别,应用方便。
- 白血病,老年 /
- 治疗 /
- 地西他滨

[1]	刘晶,马军.老年急性髓系白血病患者治疗的新进展[J].临床血液学杂志,2009,22(9):511-514.
[2]	LUBBERT M,RUTER B,SCHMID M,et al.Continued low-dose decitabine(DAC)is an active first-Line treatement of older AML patients:first results of a multicenter phase-study[J].Blood,2005,106:527-527.
[3]	CASHEN A,SCHILLER G J,LARSEN J S,et al.Phase-study of low dose decitabine for the front line treatment of older patients with acute myeloid leukemia(AML)[J].Blood,2006,108:561-561.
[4]	CHOWDHURY S,SEROPIAN S,MARKS I W.Decitabine combined with fractionated gemtuzum abozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia[J].Am J Hematol,2009,84:599-600.
[5]	SABA H I,WIJERMANS P W.Decitabinein in myelodysplastic syndroms[J].Semin Hematol,2005,42:23-31.
[6]	ISSA J P,GARCIA-MANERO G,GILES F J,et al.Phase I study of low-dose prolonged exposure schedules of the hypometylating agent 5-aza-2-deoxycytidine(decitabine)in hematopoietic malignancies[J].Blood,2004,103:1635-1640.
[7]	KANTARIAN H O,BRIEN S,GILES F,et al.Decitabine low dose Schedule(100 mg/m²/course)in myelodysplastic syndrome(MDS).Comparison of 3 different dose schedules[J].ASH,Annual Meeting Abstract,2010:2522.
[8]	宋慧慧,陈宝安,刘莆,等.地西他滨3d方案治疗骨髓增生异常综合征疗效讨论附两例病例报道[J].东南大学学报,2011,30(3):474-477.
[9]	高冲,陈宝安,刘莆,等.地西他滨治疗骨髓增生异常综合征1例报道[J].现代医学,2010,38(2):189-190.